We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LSNE Receives Approval to Manufacture Commercial Aseptic Product
News

LSNE Receives Approval to Manufacture Commercial Aseptic Product

LSNE Receives Approval to Manufacture Commercial Aseptic Product
News

LSNE Receives Approval to Manufacture Commercial Aseptic Product

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LSNE Receives Approval to Manufacture Commercial Aseptic Product"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lyophilization Services of New England, Inc. (LSNE) has announced that following an FDA Pre-Approval Inspection (PAI) in November 2014, their Harvey Road manufacturing site has received approval to manufacture commercial drug product for US distribution.

The PAI resulted in no Form 483 being issued, as there were no observations noted by the FDA. This facility is located in Bedford, NH and is dedicated to the aseptic filling and lyophilization of a product that is currently on the market.

Shawn Cain, Chief Operating Officer of LSNE stated, “We are very pleased with the positive results of the latest FDA inspection, which is another important milestone and further adds to our successful regulatory history. This approval is the culmination of years’ worth of preparation and diligence and this success helps position us for our future growth. Specifically, we are looking to expand our analytical capabilities to better support all of our client’s needs.”

LSNE has added additional capabilities across their three sites in 2014 and they plan to continue expanding in 2015. The 2015 master plan includes expansion of QC analytical testing capabilities, ICH stability chambers, additional complex/potent compound handling capabilities, as well as increased manufacturing capacity.

LSNE continues its path towards becoming the premier turn-key CMO for its clinical and commercial clients and its commitment to reduce the time and cost of bringing clients projects from bench to market.

Advertisement